# NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies

> **NCT05023486** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novita Pharmaceuticals, Inc.** · enrollment: 121 (actual)

## Conditions studied

- Advanced or Metastatic Solid Tumor Malignancies

## Interventions

- **DRUG:** NP-G2-044 Monotherapy
- **DRUG:** Anti-PD-1 Therapy
- **DRUG:** NP-G2-044 Combination therapy

## Key facts

- **NCT ID:** NCT05023486
- **Lead sponsor:** Novita Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-07
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05023486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05023486, "NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05023486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*